Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
Childhood Langerhans Cell Histiocytosis
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[41] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 41
Primary care physicians.
Pediatric surgeons.
Transplant surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[42] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 42 · NCI website
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Over many years, national and international study groups have defined risk-based therapy groups for allocation of LCH patients on the basis of mortality risk and risk of late effects of the disease.
Depending on the site and extent of disease, treatment of LCH may include observation (after biopsy or curettage), surgery, radiation therapy, or oral, topical, and intravenous medication. The recommended duration of therapy is 12 months for patients who require chemotherapy for single-system bone, skin, or lymph node involvement.
For patients with high-risk and low-risk multisystem disease, the reactivation rate after 6 months of therapy was as high as 50% on the HISTSOC-LCH-I and HISTSOC-LCH-II trials.[28,84] The German-Austrian-Dutch (Deutsche Arbeitsgemeinschaft für Leukämieforschung und Behandlung im Kindesalter [DAL]) group trials treated patients for 1 year and had fewer relapses (29%).[76,85] On the basis of these findings, the HISTSOC-LCH-III trial was designed to administer 12 months of chemotherapy for all high-risk multisystem patients and to randomly assign low-risk multisystem patients to either 6 months or 12 months of therapy. In patients with low-risk or high-risk disease who received 12 months of therapy, the reactivation rate was significantly reduced to approximately 30%.[29]
The standard treatment for LCH is based on data from international trials with large numbers of patients. However, some patients may have LCH involving only the skin, mouth, pituitary gland, or other sites not studied in these international trials. In these cases, therapy recommendations are based on case series that lack the evidence-based strength of the trials.
Clinical trials organized by the Histiocyte Society have been accruing patients on childhood treatment studies since the 1980s. Information about centers enrolling patients on these trials can be found on the ClinicalTrials.gov website.
Sources: ClinicalTrials.gov website
Treatment options for patients with low-risk, single-system or multisystem disease depend on the site of involvement, as follows:
Isolated skin involvement.
Sources: Isolated skin involvement
Skeletal involvement.
Sources: Skeletal involvement
CNS disease.
Sources: CNS disease
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for patients with isolated skin involvement include the following:
Observation. Observation is recommended for all pediatric patients with asymptomatic skin-only LCH.[48]
Sources: 48
Therapy. Therapy is suggested only for patients with symptomatic disease, which includes extensive rashes, pain, ulceration, or bleeding.
Patients with skin-only involvement need to have a complete staging evaluation because 41% of these patients referred to one center had multisystem disease requiring treatment.[48] Careful clinical (but not radiological) follow-up of young infants with skin-only LCH is suggested because progression to high-risk multisystem disease is possible. Young children with skin-only LCH should be monitored periodically for many years because 1 of 19 children and 1 of 25 children in two series developed late diabetes insipidus.[31,49]
For patients who require therapy, treatment options for symptomatic isolated skin lesions include the following:
Topical steroids. Medium- to high-potency steroids are effective, but recurrence after discontinuation is common.[50]
Sources: 50
Oral methotrexate. Oral methotrexate (20 mg/m2) weekly for 6 to 12 months.[86]
Sources: 86
Oral hydroxyurea. Oral hydroxyurea (20 mg/kg) daily for at least 12 months.[87]
Sources: 87
Oral thalidomide/lenalidomide.[88,89] Oral thalidomide 50 mg to 200 mg nightly.[88] Oral thalidomide/lenalidomide may be effective for both pediatric and adult patients.
Topical nitrogen mustard. Topical application of nitrogen mustard can be effective for cutaneous LCH that is resistant to oral therapies, but not for disease involving large areas of skin.[90,91]
Psoralen and long-wave ultraviolet A radiation (PUVA) or UVB. Psoralen and PUVA or UVB can be effective in skin LCH, but its use is limited by the potential for late skin cancers, especially in patients with light skin tones.[92,93]
Chemotherapy. Systemic chemotherapy may be used in severe and symptomatic cases.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for patients with single skull lesions of the frontal, parietal, or occipital regions, or single lesions of any other bone, include the following:
Curettage. Curettage only is the recommended therapy, when possible, for isolated bone lesions. Curettage plus injection of methylprednisolone may also be used. LCH bone lesions do not need complete excision because this may increase healing time and the risk of long-term complications. Complete excision of skull lesions, which may require grafting, is not necessary.
Low-dose radiation therapy. Local radiation therapy could be considered for an isolated lesion.[94,96][Level of evidence C3] Low-dose radiation therapy (7–10 Gy) is effective,[95,97] but its use is limited in pediatric patients to lesions that threaten organ function or are painful and not amenable to other therapies.[98,99]; [100][Level of evidence C1] In a single-institution study of 39 patients with LCH (age range, 1.5–67 years; 15 patients aged <18 years) who received radiation therapy to 46 lesions, there were no local recurrences in the 31 bony sites (median radiation therapy dose, 10.8 Gy; range, 7.5–24 Gy), and the freedom from local failure rate was 63% at 3 years in the 15 nonbone lesions (95% confidence interval, 32%–83%; P = .0008). In this study, no subsequent cancers occurred,[94] although subsequent cancers have been previously reported.[101] Skeletal complications are uncommon after the low doses that are used, but they can occur.[96]
Sources: 94 · 96 · Level of evidence C3 · 95 · 97 · 98 · 99 · 100 · Level of evidence C1 · 94 · 101 · 96
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The CNS-risk bones include the mastoid, temporal, spheroidal, zygomatic, ethmoidal, maxillary, orbital bones, sinuses, and lesions of the anterior or middle cranial fossa. Risk refers to the increased risk of progression to diabetes insipidus followed by brain (CNS) involvement.
The purpose of treating patients with isolated CNS-risk lesions is to decrease the chance of developing diabetes insipidus and other long-term neurological problems.[27]
Sources: 27
Treatment options for patients with skull lesions in the mastoid, temporal, or orbital bones include the following:
Chemotherapy. The current treatment for CNS-risk bones is 12 months of vinblastine/prednisone therapy, as per the HISTSOC-LCH-III (NCT00276757) study:[27,29][Level of evidence B1]There is controversy about whether systemic therapy is required for the first presentation of unifocal bone LCH, even in the CNS-risk bones. One retrospective review reported a series of patients with orbital or mastoid lesions who underwent only surgical curettage. The treatment was completed by a single surgeon, specialized in orbital, ear, nose, or throat diseases.[102] None of these patients developed diabetes insipidus. However, when comparing the incidence rates of diabetes insipidus in patients who received little or no chemotherapy (20%–50% incidence) with the incidence rates reported by the German-Austrian-Dutch group DAL-HX 83 trial (10% incidence in patients treated for LCH), it appears that the weight of evidence from the DAL-HX 83 trial supports chemotherapy treatment to prevent diabetes insipidus in patients with LCH in CNS-risk bones.[76,77] It should be noted, however, that the DAL-HX studies administered more drugs and treated patients for 12 months.
Sources: HISTSOC-LCH-III (NCT00276757) · 27 · 29 · Level of evidence B1 · 102 · 76 · 77
Chemotherapy. The current treatment for CNS-risk bones is 12 months of vinblastine/prednisone therapy, as per the HISTSOC-LCH-III (NCT00276757) study:[27,29][Level of evidence B1]There is controversy about whether systemic therapy is required for the first presentation of unifocal bone LCH, even in the CNS-risk bones. One retrospective review reported a series of patients with orbital or mastoid lesions who underwent only surgical curettage. The treatment was completed by a single surgeon, specialized in orbital, ear, nose, or throat diseases.[102] None of these patients developed diabetes insipidus. However, when comparing the incidence rates of diabetes insipidus in patients who received little or no chemotherapy (20%–50% incidence) with the incidence rates reported by the German-Austrian-Dutch group DAL-HX 83 trial (10% incidence in patients treated for LCH), it appears that the weight of evidence from the DAL-HX 83 trial supports chemotherapy treatment to prevent diabetes insipidus in patients with LCH in CNS-risk bones.[76,77] It should be noted, however, that the DAL-HX studies administered more drugs and treated patients for 12 months.
Weekly vinblastine (6 mg/m2) for 7 weeks for good response.
Daily prednisone (40 mg/m2) for 4 weeks, then tapered over 2 weeks.
Afterward, prednisone is given for 5 days at 40 mg/m2 every 3 weeks with the vinblastine injections (also every 3 weeks).
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for patients with vertebral or femoral bone lesions at risk of collapse include the following:
Observation. A single vertebral body lesion without soft tissue extension to the extradural space may be observed only.[103]
Sources: 103
Low-dose radiation therapy. Low-dose radiation therapy may be used to promote resolution in an isolated vertebral body lesion or a large femoral neck lesion at risk of fracture, where chemotherapy is not usually indicated (single bone lesion). Despite the low dose required (7–10 Gy), radiation therapy should be used with caution because of concerns about secondary malignancies in adjacent tissues, skeletal deformities if the growth plates are irradiated in very young children,[96,101] or if the thyroid gland would be in the radiation field in cervical vertebral lesions.
Chemotherapy. Patients with soft tissue extension from vertebral lesions are often treated successfully with chemotherapy,[46][Level of evidence C2] but prolonged therapy does not appear to be needed beyond the period required to reduce the mass and any risk to the spinal cord. The risk of reactivation of a single bone lesion was only 9% in one large retrospective series.[104]
Sources: 46 · Level of evidence C2 · 104
Bracing or spinal fusion. When instability of the cervical vertebrae and/or neurological symptoms are present, bracing—or rarely, spinal fusion—may be needed.[105]
Sources: 105
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for patients with multiple bone lesions (single-system multifocal bone lesions) at risk of collapse include the following:
Chemotherapy. The most commonly used systemic chemotherapy regimen is the combination of vinblastine and prednisone. Based on the results of the HISTSOC-LCH-III (NCT00276757) trial, 12 months of treatment with weekly vinblastine (6 mg/m2) for 7 weeks, then every 3 weeks, is used for good responders.[29] Prednisone (40 mg/m2) is given daily for 4 weeks, then tapered over 2 weeks. Afterward, prednisone is given for 5 days at 40 mg/m2 every 3 weeks with the vinblastine injections. A short treatment course (<6 months) with only a single agent (e.g., prednisone) is not sufficient, and the number of relapses is higher. A reactivation rate of 18% was reported with a multidrug treatment regimen that was used for 6 months versus a historical reactivation rate of 50% to 80% with surgery alone or with a single-drug treatment regimen.[106] A comparison of results from two trials in Japan revealed no improvement in progression-free survival rates (66% vs. 65%) when additional prednisone and a prolonged maintenance phase were added.[107]
Sources: HISTSOC-LCH-III (NCT00276757) · 29 · 106 · 107
For information about additional agents used to treat multifocal bone LCH, see the Multiple bone lesions in combination with skin, lymph node, or diabetes insipidus (low-risk multisystem LCH) section.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for patients with multiple bone lesions in combination with skin, lymph node, or diabetes insipidus (low-risk multisystem LCH) include the following:
Chemotherapy (vinblastine and prednisone in combination). Based on the results of the randomized HISTSOC-LCH-III (NCT00276757) trial, the same chemotherapy regimen of vinblastine and prednisone, as described above, is used for 12 months. Patients without risk-organ involvement who were randomly assigned to receive 12 months of treatment with vinblastine/prednisone had a lower 5-year reactivation rate (37%) than did patients who received only 6 months of treatment (54%; P = .03) and patients treated with historical 6-month schedules (52% [HISTSOC-LCH-I] and 48% [HISTSOC-LCH-II]; P < .001). Most disease reactivations were in bone, skin, or other non-risk locations.[29]Patients with low-risk multisystem LCH have a survival rate of almost 100%, but reactivations were shown to be major risk factors for significant late effects on the DAL and Histiocyte Society trials.[29,76]
Sources: HISTSOC-LCH-III (NCT00276757) · above · 29 · 29 · 76
Chemotherapy (other regimens). Other chemotherapy regimens have also been effective, including the following:
Chemotherapy (other regimens). Other chemotherapy regimens have also been effective, including the following:
Vincristine, cytarabine, and prednisone in combination.[108][Level of evidence C2] This combination has proven effectiveness as frontline or salvage therapy. However, prednisone is now given for a much shorter time than was originally published (52 weeks): 4 weeks at 40 mg/m2 then tapered to 20 mg/m2 by week 6 during the induction phase, and for 5 days every 3 weeks at 20 mg/m2 with a single dose of vincristine and 5 days of cytarabine during maintenance.
Sources: 108 · Level of evidence C2
Cladribine. Cladribine given at 5 mg/m2 per day for 5 days every 3 weeks for two to six cycles can be an effective salvage therapy for recurrent bone or low-risk multisystem disease.[109][Level of evidence C2] More than six cycles is not recommended because of the risk of cumulative cytopenias.
Sources: 109 · Level of evidence C2
Bisphosphonate therapy. Bisphosphonate therapy can also be effective for treating LCH bone lesions.[110,111][Level of evidence C2] A nationwide survey from Japan described 16 children treated with bisphosphonates for bone LCH. None had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course given at 4-week intervals. In 12 of 16 patients, all active lesions including skin (n = 3) and soft tissues (n = 3) resolved. Eight patients remained disease free at a median of 3.3 years.[112] Other bisphosphonates such as zoledronate have been used to successfully treat bone LCH.[113]Although bisphosphonates are used for bone LCH, some publications report response in other organs, such as skin.[111,112]
Sources: 110 · 111 · Level of evidence C2 · 112 · 113 · 111 · 112
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
CNS LCH lesions include the following:
Mass lesions or tumors in the cerebrum, cerebellum, or choroid plexus.
Mass lesions of the hypothalamic-pituitary axis that are always associated with diabetes insipidus and are often associated with other endocrinopathies.
Drugs that cross the blood-brain barrier, such as cladribine, or other nucleoside analogs, such as cytarabine, are used for active CNS LCH lesions.
Treatment options for patients with CNS LCH lesions include the following:
Chemotherapy (cladribine). Treatment of mass lesions with cladribine has been effective in 13 reported cases.[114,115]; [116][Level of evidence C2] Mass lesions included enlargement of the hypothalamic-pituitary axis, parenchymal mass lesions, and leptomeningeal involvement. Doses of cladribine ranged from 5 mg/m2 to 13 mg/m2, given at varying frequencies.[116][Level of evidence C2]
Sources: 114 · 115 · 116 · Level of evidence C2 · 116 · Level of evidence C2
Chemotherapy (other regimens). Patients with LCH and mass lesions in the hypothalamic-pituitary region, the choroid plexus, the grey matter, or the white matter may also respond to standard LCH chemotherapy.[117,118][Level of evidence C3] Treatment with vinblastine with or without corticosteroids for patients with CNS mass lesions (20 patients; mainly pituitary) demonstrated objective responses in 15 patients. Of 20 patients, 5 achieved complete responses and 10 achieved partial responses.
Sources: 117 · 118 · Level of evidence C3
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
There is no established optimal therapy for cND-LCH, and assessment of response can be difficult.[119]
Sources: 119
In cND-LCH, T2 FLAIR hyperintense signals are present, most often in the cerebellar white matter, pons, basal ganglia, and, sometimes, in the cerebrum. It is not clear whether LCH changes in the cerebellum, pons, and basal ganglia diagnosed by MRI and without clinical neurological findings should be treated. Early studies suggested that not all LCH-related radiological changes progressed to clinical neurodegenerative disease. However, treatment in the early stages of clinical disease before permanent damage occurs appears to be important. The current recommendation is ongoing neurological evaluation both clinically and with MRI scanning. Therapy starts as soon as clinical neurodegenerative disease progression is noted. It is unclear whether progressive radiological changes should be an indication for treatment.[38]
Sources: 38
Other drugs used in active LCH, such as dexamethasone, cladribine, and infliximab, have been used in small numbers of patients with mixed results. Many of these agents may result in the complete or partial resolution of radiographic findings, but definitive clinical response rates have not been rigorously defined.[38,120-123]; [116][Level of evidence C2]
Sources: 38 · 120 · 123 · 116 · Level of evidence C2
Newer treatment options for patients with cND-LCH include the following:
BRAF V600E inhibitor therapy. For more information, see the Treatment of recurrent, refractory, or progressive high-risk disease: multisystem LCH section. Clinical experience suggests that BRAF V600E inhibitor therapy may be the most effective therapy for improving neurological symptoms in cND-LCH, but the therapy may need to be continued lifelong.[82][Level of evidence C3]; [124]
Sources: Treatment of recurrent, refractory, or progressive high-risk disease: multisystem LCH · 82 · Level of evidence C3 · 124
Chemotherapy. A study using cytarabine with or without vincristine for up to 24 months reported improved clinical and MRI findings in some patients and stable disease in the others.[38][Level of evidence C1] Seven of eight patients were monitored for more than 8 years after stopping therapy and had stable neurological and radiographic findings.In the Japan LCH Study Group (JLSG)-96 Protocol, cytarabine failed to prevent the onset of neurodegenerative syndrome. Patients received cytarabine 100 mg/m2 daily on days 1 to 5 during induction and 150 mg/m2 on day 1 of each maintenance cycle (every 2 weeks for 6 months). Three of 91 patients developed neurodegenerative disease, which is similar to the rate reported for patients on the Histiocyte Society studies.[125][Level of evidence B4]
Sources: 38 · Level of evidence C1 · 125 · Level of evidence B4
Rituximab. Eight patients with neurological symptoms for a median of 8 years and who developed new symptoms after being treated with cytarabine received rituximab (375 mg/m2 weekly for 4 weeks, repeated every 3 months and increased to 555 mg/m2 for no improvement or worsening of symptoms) for variable lengths of time. Clinical symptoms improved in seven of eight patients (five patients improved within 1 month of starting rituximab). Five patients remained free of progressive clinical symptoms for 3 years or longer.[126][Level of evidence C3]
Sources: 126 · Level of evidence C3
Early recognition of clinical neurodegeneration and early institution of therapy appear to be vital for success of therapy. Studies combining MRI findings together with CSF markers of demyelination, to identify patients who require therapy even before onset of clinical symptoms, are under way in several countries. Studies of CSF and serum biomarkers in an attempt to predict and prevent neurodegenerative disease are also ongoing.[119]
Sources: 119
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Over many years, national and international study groups have defined risk-based therapy groups for allocation of LCH patients on the basis of mortality risk and risk of late effects of the disease.
Depending on the site and extent of disease, treatment of LCH may include observation (after biopsy or curettage), surgery, radiation therapy, or oral, topical, and intravenous medication. The recommended duration of therapy is 12 months for patients who require chemotherapy for single-system bone, skin, or lymph node involvement.
For patients with high-risk and low-risk multisystem disease, the reactivation rate after 6 months of therapy was as high as 50% on the HISTSOC-LCH-I and HISTSOC-LCH-II trials.[28,85] The German-Austrian-Dutch (DAL) group trials treated patients for 1 year and had fewer relapses (29%).[76,85] On the basis of these findings, the HISTSOC-LCH-III trial was designed to administer 12 months of chemotherapy for all high-risk multisystem patients and to randomly assign low-risk multisystem patients to either 6 months or 12 months of therapy. In patients with low-risk or high-risk disease who received 12 months of therapy, the reactivation rate was significantly reduced to approximately 30%.[29]
The standard treatment for LCH is based on data from international trials with large numbers of patients. However, some patients may have LCH involving only the skin, mouth, pituitary gland, or other sites not studied in these international trials. In these cases, therapy recommendations are based on case series that lack the evidence-based strength of the trials.
Clinical trials organized by the Histiocyte Society have been accruing patients on childhood treatment studies since the 1980s. Information about centers enrolling patients on these trials can be found on the ClinicalTrials.gov website.
Sources: ClinicalTrials.gov website
Treatment options for patients with high-risk multisystem disease (spleen, liver, and bone marrow involving one or more sites) include the following:
Chemotherapy.
Sources: Chemotherapy
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Evidence (chemotherapy):
In the HISTSOC-LCH-II and HISTSOC-LCH-III (NCT00276757) studies, the standard treatment arm consisted of vinblastine and prednisone, as described above, but mercaptopurine was added to the continuation phase of the protocol.[27,76][Level of evidence A1]
Sources: HISTSOC-LCH-III (NCT00276757) · above · 27 · 76 · Level of evidence A1
In the HISTSOC-LCH-II and HISTSOC-LCH-III (NCT00276757) studies, the standard treatment arm consisted of vinblastine and prednisone, as described above, but mercaptopurine was added to the continuation phase of the protocol.[27,76][Level of evidence A1]
The standard therapy length recommended for LCH involving the spleen, liver, or bone marrow (high-risk organs) is now 12 months, based on the DAL-HX 83 and HISTSOC-LCH-III studies.
In the HISTSOC-LCH-II study, patients were randomly assigned to treatment with either vinblastine, prednisone, and mercaptopurine or vinblastine, prednisone, mercaptopurine, and etoposide.[28][Level of evidence A1]
Sources: 28 · Level of evidence A1
In the HISTSOC-LCH-II study, patients were randomly assigned to treatment with either vinblastine, prednisone, and mercaptopurine or vinblastine, prednisone, mercaptopurine, and etoposide.[28][Level of evidence A1]
There was no statistically significant difference in outcomes (response at 6 weeks, 5-year probability of survival, relapses, and permanent consequences) between the two treatment groups. Hence, etoposide has not been used in subsequent Histiocyte Society trials.
Late review of the results, however, reported reduced mortality for patients with risk-organ involvement in the etoposide arm.
Although controversial, a comparison of patients in the HISTSOC-LCH-I trial with patients in the HISTSOC-LCH-II trial suggested the following results:[26]
Sources: 26
Although controversial, a comparison of patients in the HISTSOC-LCH-I trial with patients in the HISTSOC-LCH-II trial suggested the following results:[26]
Increased treatment intensity promoted additional early responses and reduced mortality.
It is important to note that those studies included lungs as risk organs. However, subsequent analyses have shown that lung involvement lacks prognostic significance.
In the HISTSOC-LCH-III (NCT00276757) study, risk-organ–affected patients were randomly assigned to receive either vinblastine/prednisone/mercaptopurine or vinblastine/prednisone/mercaptopurine plus methotrexate (intravenous during the induction phase and oral in the continuation phase).[29]
Sources: HISTSOC-LCH-III (NCT00276757) · 29
In the HISTSOC-LCH-III (NCT00276757) study, risk-organ–affected patients were randomly assigned to receive either vinblastine/prednisone/mercaptopurine or vinblastine/prednisone/mercaptopurine plus methotrexate (intravenous during the induction phase and oral in the continuation phase).[29]
The response rates at 6 and 12 weeks and OS were no different between arms; however, there were significantly increased grade 3 and grade 4 toxicities in patients who received methotrexate.
An important finding of the HISTSOC-LCH-III study was that the survival of patients with high-risk LCH on both arms of the study was significantly improved compared with that of patients on the earlier HISTSOC-LCH-II study, even though the standard arm used the same drugs. Possible explanations for better survival include the following:
In the HISTSOC-LCH-III (NCT00276757) study, risk-organ–affected patients were randomly assigned to receive either vinblastine/prednisone/mercaptopurine or vinblastine/prednisone/mercaptopurine plus methotrexate (intravenous during the induction phase and oral in the continuation phase).[29] › An important finding of the HISTSOC-LCH-III study was that the survival of patients with high-risk LCH on both arms of the study was significantly improved compared with that of patients on the earlier HISTSOC-LCH-II study, even though the standard arm used the same drugs. Possible explanations for better survival include the following:
A second 6-week induction phase of weekly vinblastine with oral prednisone was administered for 3 days per week. This reinduction phase was given to all patients who did not achieve an NAD status by the end of the 6-week induction phase, before going onto the every-3-weeks maintenance courses. The rate of NAD increased after the second induction phase; this course may have played a significant role in the improved survival rate.
Better supportive care.
Earlier change to an effective salvage strategy for nonresponsive lesions.
In the HISTSOC-LCH-III (NCT00276757) study, risk-organ–affected patients were randomly assigned to receive either vinblastine/prednisone/mercaptopurine or vinblastine/prednisone/mercaptopurine plus methotrexate (intravenous during the induction phase and oral in the continuation phase).[29]
It should be noted that although survival was improved in the HISTSOC-LCH-III study, only 60% of patients achieved an NAD status in risk organs after a year of therapy, and 25% to 29% of patients relapsed.
In the JLSG-96 trial, treatment included a 6-week induction regimen of cytarabine, vincristine, and prednisolone followed by 6 months of maintenance therapy with cytarabine, vincristine, prednisolone, and low-dose intravenous methotrexate. If patients had a poor response to the initial regimen, they were switched to a salvage regimen of intensive combination doxorubicin, cyclophosphamide, methotrexate, vincristine, and prednisolone.[125][Level of evidence B1]
Sources: 125 · Level of evidence B1
In the JLSG-96 trial, treatment included a 6-week induction regimen of cytarabine, vincristine, and prednisolone followed by 6 months of maintenance therapy with cytarabine, vincristine, prednisolone, and low-dose intravenous methotrexate. If patients had a poor response to the initial regimen, they were switched to a salvage regimen of intensive combination doxorubicin, cyclophosphamide, methotrexate, vincristine, and prednisolone.[125][Level of evidence B1]
The 5-year response rate was 78%, and the OS rate was 95% for patients with multisystem disease.
Diabetes insipidus occurred in 8.9% of patients with multisystem disease.
Similar to the HISTSOC-LCH-III (NCT00276757) study, the important finding of this study was the increased survival compared with previous JLSG studies and the HISTSOC-LCH-II study. This was attributed to the early change to a more effective salvage therapy for patients with nonresponsive disease, as well as better supportive care.
Sources: HISTSOC-LCH-III (NCT00276757)
The study had a high reactivation rate, which prompted several changes, including an increase in the duration of the trial to 12 months and the addition of vinblastine, prednisone, mercaptopurine, and methotrexate.[62]
Sources: 62
The JLSG-02 protocol was similar to the JLSG-96 study, except that cyclosporine was added to the reinduction of poor responders and the length of treatment was increased to 54 weeks for good responders and 60 weeks for poor responders.[136][Level of evidence B1]
Sources: 136 · Level of evidence B1
The JLSG-02 protocol was similar to the JLSG-96 study, except that cyclosporine was added to the reinduction of poor responders and the length of treatment was increased to 54 weeks for good responders and 60 weeks for poor responders.[136][Level of evidence B1]
Despite a markedly increased intensity of treatment, the event-free survival (EFS) rates were only 46% for high-risk patients and 70% for low-risk patients. In the HISTSOC-LCH-III study, the EFS rates were 33% for high-risk patients and 50% for low-risk patients.[137]
Sources: 137
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following are examples of national and/or institutional clinical trials that are currently being conducted:
HISTSOC-LCH-IV (NCT02205762) (LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With LCH): On the basis of features at presentation and response to treatment, the LCH-IV study tailors treatment to one of the following seven strata:
Sources: HISTSOC-LCH-IV (NCT02205762)
HISTSOC-LCH-IV (NCT02205762) (LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With LCH): On the basis of features at presentation and response to treatment, the LCH-IV study tailors treatment to one of the following seven strata:
Stratum I: First-line treatment for multisystem LCH patients (group 1) and patients with single-system LCH with multifocal bone or CNS-risk lesions (group 2).
Stratum II: Second-line treatment for non–risk-organ patients (patients without risk-organ involvement who fail first-line therapy or have a reactivation after completion of first-line therapy).
Stratum III: Salvage treatment for risk-organ LCH (patients with dysfunction of risk organs who fail first-line therapy).
Stratum IV: Hematopoietic stem cell transplant for risk-organ LCH (patients with dysfunction of risk organs who fail first-line therapy).
Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS LCH.
Stratum VI: Natural history and management of other single-system LCH (patients who do not need systemic therapy at the time of diagnosis).
Stratum VII (long-term follow up): All patients, regardless of previous therapy, will be monitored for reactivation or permanent consequences once complete disease resolution has been achieved and the respective protocol treatment has been completed.
NCT02670707 (Cytarabine or Vinblastine Sulfate and Prednisone in Treating Patients With LCH): The purpose of this trial is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH.
Sources: NCT02670707
It is preferable that patients with LCH be enrolled in a clinical trial whenever possible so that advances in therapy can be achieved more quickly, using evidence-based recommendations, and to ensure optimal care. Information about clinical trials for LCH in children is available from the NCI website, Histiocyte Society website, and the North American Consortium for Histiocytosis (NACHO) website.
Sources: NCI website · Histiocyte Society website · North American Consortium for Histiocytosis (NACHO) website
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The optimal therapy for patients with recurrent, refractory, or progressive LCH has not been determined.
Treatment options for patients with recurrent, refractory, or progressive low-risk, single-system or multisystem LCH include the following:
Chemotherapy.
Sources: Chemotherapy
Bisphosphonate therapy.
Sources: Bisphosphonate therapy
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The following chemotherapy regimens have been used to treat patients with recurrent, refractory, or progressive low-risk disease:
Vinblastine and prednisone. Patients with recurrent bone disease that recurs months after vinblastine and prednisone are stopped can benefit from treatment with a reinduction of vinblastine weekly and daily prednisone for 6 weeks. If there is NAD or very little evidence of active disease, treatment can be changed to every 3 weeks, with the addition of oral mercaptopurine nightly.[106]
Sources: 106
Vincristine, prednisone, and cytarabine. An alternative treatment regimen for patients with any combination of low-risk disease sites employs vincristine, prednisone, and cytarabine.[108][Level of evidence C3]
Sources: 108 · Level of evidence C3
Single-agent cytarabine. Single-agent cytarabine at doses of 100 to 170 mg/m2 per day for five days has also proven to be effective.[139]
Sources: 139
Cladribine. Cladribine at 5 mg/m2 per day for 5 days per course has demonstrated effectiveness for recurrent low-risk LCH (multifocal bone and low-risk multisystem LCH), with very little toxicity.[109][Level of evidence C3] Cladribine therapy should, if possible, be limited to a maximum of six cycles to avoid cumulative and potentially long-lasting cytopenias.In a study of 44 pediatric patients with low-risk LCH who were treated with cladribine, 5 patients achieved complete remissions after a median follow-up of over 5 years.[140] Grade 3 or higher neutropenia occurred in 32% of patients, and grade 3 or higher lymphopenia occurred in 72% of patients. Patients with stable disease or partial responses after 6 months of treatment may ultimately attain a complete response.
Sources: 109 · Level of evidence C3 · 140
Clofarabine. Clofarabine is a proven effective therapy for patients with multiple relapses of low-risk or high-risk LCH.[141][Level of evidence C3]
Sources: 141 · Level of evidence C3
Hydroxyurea, alone or in combination with oral methotrexate. In one single-center trial, treatment with hydroxyurea, alone or in combination with oral methotrexate, reported the following results:[87][Level of evidence C3]
Sources: 87 · Level of evidence C3
Hydroxyurea, alone or in combination with oral methotrexate. In one single-center trial, treatment with hydroxyurea, alone or in combination with oral methotrexate, reported the following results:[87][Level of evidence C3]
Twelve of fifteen patients with low-risk recurrent LCH had responses to treatment.
Thalidomide. A phase II trial of thalidomide in patients with LCH (ten low-risk patients; six high-risk patients) who failed primary treatment and at least one secondary regimen demonstrated the following:[88][Level of evidence C3]
Sources: 88 · Level of evidence C3
Thalidomide. A phase II trial of thalidomide in patients with LCH (ten low-risk patients; six high-risk patients) who failed primary treatment and at least one secondary regimen demonstrated the following:[88][Level of evidence C3]
Of the ten low-risk patients, four had complete responses and three had partial responses. Complete response was defined as healing of bone lesions on plain radiographs (n = 3) or complete resolution of skin rash (n = 4, including 3 with bone lesions that had complete resolution). Partial response was defined as healing of a bone lesion, but then worsening of a skin rash that was partially resolved.
Dose-limiting toxicities, such as neuropathy and neutropenia, may limit the overall usefulness of thalidomide.
Thalidomide is not a significant agent in treating pediatric patients.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Bisphosphonate therapy is also effective for treating patients with recurrent LCH bone lesions.[142]
Sources: 142
Evidence (bisphosphonate therapy):
In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]
Sources: 110 · Level of evidence C3
In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]
Of the 16 patients, 12 were successfully treated.
Skin and soft tissue LCH lesions also resolved in the responding patients.
Eight of the 12 patients remained disease free at a median of 3.3 years.
Other bisphosphonates, such as zoledronate and oral alendronate, have also been successful in treating bone LCH.[111-113][Level of evidence C3]
Sources: 111 · 113 · Level of evidence C3
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Data from the DAL group studies showed that patients with high-risk multisystem LCH who had progressive disease by week 6 of standard induction treatment or who did not achieve at least a partial response by week 12 had only a 10% chance of survival.[27] These results were consistent with those of the less-intensive HISTSOC-LCH-II trial in which patients treated with vinblastine/prednisone who did not respond well by week 6 had a 27% chance of survival, compared with 52% for good responders.[28][Level of evidence A1] To improve on these results, patients with poorly responsive disease need to move to salvage strategies by week 6 for progressive disease and no later than week 12 for those without at least a good response.
Sources: 27 · 28 · Level of evidence A1
Treatment options for patients with recurrent, refractory, or progressive high-risk multisystem LCH include the following:
Chemotherapy.
Sources: Chemotherapy
Targeted therapy (e.g., MAPK inhibitors).
Sources: Targeted therapy
Hematopoietic stem cell transplant (HSCT).
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Evidence (cladribine and cytarabine):
Ten patients with refractory high–risk-organ involvement (liver, spleen, or bone marrow) and resistant multisystem low–risk-organ involvement were treated with an intensive acute myeloid leukemia–like protocol consisting of cladribine and cytarabine.[143][Level of evidence C3] The follow-up HISTSOC-LCH-S-2005 trial accrued 27 patients and demonstrated the following results:[144]
Sources: 143 · Level of evidence C3 · 144
Ten patients with refractory high–risk-organ involvement (liver, spleen, or bone marrow) and resistant multisystem low–risk-organ involvement were treated with an intensive acute myeloid leukemia–like protocol consisting of cladribine and cytarabine.[143][Level of evidence C3] The follow-up HISTSOC-LCH-S-2005 trial accrued 27 patients and demonstrated the following results:[144]
The progression-free survival rate was 63%, and the 5-year OS rate was 85% in this refractory, high-risk patient population.
All patients developed grade 4 hematologic toxicity, and five of these patients had severe sepsis.
For centers that cannot provide the intensive supportive care needed for this protocol, an alternative protocol using lower doses of cladribine (5 mg/m2/day × 5 days) and cytarabine (100 mg/m2/day × 4 days) was published.[145][Level of evidence C2]
Sources: 145 · Level of evidence C2
For centers that cannot provide the intensive supportive care needed for this protocol, an alternative protocol using lower doses of cladribine (5 mg/m2/day × 5 days) and cytarabine (100 mg/m2/day × 4 days) was published.[145][Level of evidence C2]
Six of nine patients achieved NAD status, and one patient had improved status after six courses.
Some patients received maintenance therapy.
Seven of nine patients remained in complete remission, with a median follow-up of 6.5 years.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Patients who did not respond to treatment with cladribine were reported to respond to treatment with clofarabine.[146]; [147][Level of evidence C2]
Sources: 146 · 147 · Level of evidence C2
Evidence (clofarabine):
Eleven patients with recurrent multisystem high-risk and low-risk disease were treated with clofarabine.[141]
Sources: 141
Eleven patients with recurrent multisystem high-risk and low-risk disease were treated with clofarabine.[141]
The OS rate was 90%.
If confirmed in prospective trials, the reduced toxicity of this regimen compared with the cladribine/cytarabine combination could be advantageous, despite the cost of the drug.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The discovery that most patients with LCH have BRAF V600E or other variants that result in activation of the RAS pathway suggests that new therapies that target molecules within this pathway (MAP2K/ERK inhibitors) will become an important part of LCH therapy.
Evidence (vemurafenib):
Forty-four LCH patients with risk-organ involvement and ten LCH patients without risk-organ involvement were treated with vemurafenib. Of the 44 risk-organ–involved patients, 31 received vemurafenib as their original therapy and 13 received vemurafenib as treatment after disease progression. The ten risk-organ–negative patients also received vemurafenib after disease progression.[148][Level of evidence C3]
Sources: 148 · Level of evidence C3
Forty-four LCH patients with risk-organ involvement and ten LCH patients without risk-organ involvement were treated with vemurafenib. Of the 44 risk-organ–involved patients, 31 received vemurafenib as their original therapy and 13 received vemurafenib as treatment after disease progression. The ten risk-organ–negative patients also received vemurafenib after disease progression.[148][Level of evidence C3]
After 8 weeks of treatment, there were 38 complete responses and 16 partial responses. Most patients were treated for 6 months.
Thirty patients stopped taking vemurafenib; 24 of these patients subsequently relapsed: 72% of patients at 6 months and 84% of patients at 12 months off therapy.
The relapse rate was 95% for patients with risk-organ involvement and 57% for patients without risk-organ involvement.
Relapse was associated with the persistence of circulating BRAF-positive cells.
The most frequent adverse effects of the drug were dermatologic. In a review of 57 patients with LCH who received vemurafenib for refractory disease, 72% of patients had cutaneous adverse events, 86% of which were grade 1 or grade 2.[149] Most patients had photosensitivity, keratosis pilaris, macular or follicular rashes, or xerosis. No skin tumors were observed.
Sources: 149
A systematic review and meta-analysis evaluated the efficacy and safety of vemurafenib for the treatment of patients with LCH. The analysis found 416 studies, 22 of which fit the inclusion criteria. There were 104 patients with relapsed or refractory disease and 3 patients with newly diagnosed disease.[150]
Sources: 150
A systematic review and meta-analysis evaluated the efficacy and safety of vemurafenib for the treatment of patients with LCH. The analysis found 416 studies, 22 of which fit the inclusion criteria. There were 104 patients with relapsed or refractory disease and 3 patients with newly diagnosed disease.[150]
With vemurafenib treatment, the median time to first response was 1 week and the median time to best response was 5.25 months.
Sixty-two patients (58%) achieved NAD status, and 36% had decreased active disease.
The overall response rate was 94.4%.
Major toxicity included rash and photosensitivity.
The authors concluded that vemurafenib was highly efficacious and safe to treat patients with refractory LCH, but the duration of therapy has yet to be established.
A multicenter, retrospective analysis of experiences that used various MAPK inhibitors to treat 21 pediatric patients with LCH who had failed at least one previous therapy (median, three previous therapies) demonstrated the following:[124][Level of evidence C3]
Sources: 124 · Level of evidence C3
A multicenter, retrospective analysis of experiences that used various MAPK inhibitors to treat 21 pediatric patients with LCH who had failed at least one previous therapy (median, three previous therapies) demonstrated the following:[124][Level of evidence C3]
An overall response rate of 86% (complete response, 19%; partial response, 67%).
Stable disease in 10% of patients.
The most frequent toxicities were skin rashes and arthralgias. Other toxicities included neutropenia, fatigue, and uveitis.
Evidence (dabrafenib with or without trametinib):
One study compared dabrafenib alone (13 patients) with dabrafenib and trametinib (12 patients) for the treatment of patients with relapsed or progressive LCH.[151]
Sources: 151
One study compared dabrafenib alone (13 patients) with dabrafenib and trametinib (12 patients) for the treatment of patients with relapsed or progressive LCH.[151]
With a 2-year follow-up, the responses were similar in both arms (46.2% complete response, 30.8% regressive disease, and 23.1% stable disease for dabrafenib alone vs. 33.3% complete response, 25.0% regressive disease, and 25.0% stable disease for combination therapy).
Adverse events were also similar and included pyrexia and vomiting, cough, and increased serum creatinine.
This study would suggest that combination therapy is not more effective in patients with LCH. However, more data are needed.
Although malignancies such as squamous cell carcinoma have been reported in adults treated with MAPK inhibitors, such malignancies have not been reported in pediatric patients.[149] Like adults, children develop acneform rashes, photosensitivity, diarrhea, and, sometimes, myalgias.[124]
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
HSCT has been used in patients with multisystem high–risk-organ involvement that is refractory to chemotherapy.[142,154-157] Early results showing very high treatment-related mortality in these ill young infants led to the development of reduced-intensity conditioning.
Evidence (reduced-intensity conditioning vs. myeloablative conditioning for HSCT):
A review from the United Kingdom suggested that in transplant centers that have LCH HSCT experience, there was no advantage to reduced-intensity conditioning in their setting.[158][Level of evidence C2]
Sources: 158 · Level of evidence C2
A review from the United Kingdom suggested that in transplant centers that have LCH HSCT experience, there was no advantage to reduced-intensity conditioning in their setting.[158][Level of evidence C2]
Reduced-intensity conditioning provided no OS advantage over myeloablative conditioning for LCH patients; the relapse rate after reduced-intensity conditioning was significantly higher (28%) than the relapse rate after myeloablative conditioning (8%).
Many of the patients who received reduced-intensity conditioning and relapsed were successfully re-treated with chemotherapy alone.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Seventy-five percent of children with sclerosing cholangitis will not respond to chemotherapy because the LCH is no longer active, but the fibrosis and sclerosis remain. Despite the limitations, liver biopsy may be the only way to distinguish active LCH from end-stage fibrosis. Liver transplant is the only alternate treatment when hepatic function worsens. A review of 60 patients with LCH (55 children) who underwent hepatic transplant for LCH-associated liver failure reported a 5-year survival rate of 82%. Posttransplant rejection occurred in 55% of patients, 22% of whom received a second transplant. The 5-year overall graft survival rate was 62% for patients who underwent deceased-donor liver transplant and 81% for patients who underwent living-donor liver transplant (not statistically significant). Nine patients died (15%). There was one case of posttransplant lymphoproliferative disease (PTLD), and no data on LCH recurrences. The authors conducted a literature review to identify an additional 50 patients with LCH who underwent a liver transplant. Of these patients, 47% experienced rejection, 11% had PTLD, and 8% had recurrent LCH. Seven patients (14%) with graft loss were treated with retransplant.[159][Level of evidence C2]
Sources: 159 · Level of evidence C2
Case reports and case series have documented the efficacy of MAPK inhibitors for the treatment of progressive hepatic LCH.[148,160]
Some patients develop a macrophage activation of their marrow. This could be confusing to clinicians, who may think the patient has hemophagocytic lymphohistiocytosis (HLH) and LCH. The best therapy for this life-threatening manifestation is not clear because it tends not to respond well to standard HLH therapy. Clofarabine, anti-CD52 antibody alemtuzumab, or reduced-intensity allogeneic stem cell transplant could be considered.[161][Level of evidence C3] It is unknown whether newer HLH therapies, such as the antibody to interferon-gamma or the JAK-STAT inhibitor ruxolitinib, will be more effective in the LCH-macrophage activation than the above options.
Sources: 161 · Level of evidence C3
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT04079179 (Cobimetinib for the Treatment of Refractory LCH): This study is open to children or adults with relapsed or refractory LCH or other newly diagnosed, relapsed, or refractory histiocytic disorders.
Sources: NCT04079179
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Response assessment remains one of the most difficult areas in LCH therapy. It is easier when there is a specific area that can be monitored clinically or with ultrasonography, CT, PET, or MRI scans, such as the skin, hepato/splenomegaly, and other mass or lytic bone lesions. Clinical judgment, including evaluation of pain and other symptoms, remains important.
Bone lesions may take many months to heal and are difficult to evaluate on plain radiographs, although sclerosis around the periphery of a bone lesion suggests healing. CT or MRI scans are useful in assessing response of a soft tissue mass associated with a bone lesion, but are not particularly helpful in assessing the response of lytic bone lesions. Technetium Tc 99m bone scans remain positive in healing bone. PET scans may be helpful in monitoring the response to therapy because the intensity of the PET image diminishes with the response of lesions and healing of bone.[17]
Sources: 17
For children or adults with lung LCH, pulmonary function testing and high-resolution CT scans are sensitive methods for detecting disease progression.[20] Residual interstitial changes reflecting residual fibrosis or residual inactive cysts must be distinguished from active disease; somatostatin analog scintigraphy may be useful in this regard.[162]
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatments that have been used in the past but are no longer recommended for pediatric patients with LCH include cyclosporine [163] and interferon-alpha.[164]
Extensive surgery is also not indicated. For lesions of the mandible, extensive surgery may destroy any possibility of secondary tooth development. Surgical resection of groin or genital lesions is contraindicated because these lesions can be healed by chemotherapy.
Radiation therapy use in LCH has been significantly reduced in pediatric patients, and even low-dose radiation therapy should be limited to single-bone, vertebral body lesions or other single-bone lesions compressing the spinal cord or optic nerve that do not respond to chemotherapy or are painful and not amenable to other therapy.[94,101,165]
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The reported frequency of long-term consequences of LCH has ranged from 20% to 70%. Children with low–risk-organ involvement (skin, bones, lymph nodes, or pituitary gland) have an approximately 20% chance of developing long-term sequelae.[30,166]; [167][Level of evidence B4] Patients with multisystem involvement have a reported rate of long-term complications of approximately 70% when treatment was only 6 months.[30,101,168,169] However, the extent of long-term sequelae in patients who are treated for a year has not been reported.
Sources: 30 · 166 · 167 · Level of evidence B4 · 30 · 101 · 168 · 169
This wide variation in frequency results from case definition, sample size, therapy used, method of data collection, and follow-up duration. Quality-of-life studies have reported the following:
In one study of long-term survivors of skeletal LCH, the quality-of-life scores were not significantly different from those of healthy control children and adults.[104] In addition, the quality-of-life scores were very similar between those with and without permanent sequelae.
Sources: 104
In another study of 40 patients who were carefully screened for late effects, adverse quality-of-life scores were found in more than 50% of patients.[40] Seventy-five percent of patients had detectable long-term sequelae. Hypothalamic/pituitary dysfunction (50%), cognitive dysfunction (20%), and cerebellar involvement (17.5%) were the most common side effects.
Sources: 40
The late effects of LCH may occur in the following body systems:
Endocrine. Patients with diabetes insipidus are at risk of panhypopituitarism and should be monitored carefully for adequacy of growth and development. In a retrospective review of 141 patients with LCH and diabetes insipidus, 43% developed growth hormone (GH) deficiency.[101,168,169] The 5-year risk of GH deficiency among children with LCH and diabetes insipidus was 35%, and the 10-year risk was 54%. There was no increased reactivation of LCH in patients who received GH compared with those who did not.[168] Growth and development problems are more frequent because of the young age at presentation and the more toxic effects of long-term prednisone therapy in the very young child.
Special senses (hearing loss). Hearing loss has been found in 38% of children who were treated for LCH.[101] Seventy percent of patients with LCH in this study had ear involvement, which included aural discharge, mastoid swelling, and hearing loss. Of those with CT or MRI abnormalities in the mastoid, 59% had hearing loss.[170][Level of evidence C1]
Sources: 101 · 170 · Level of evidence C1
Neurological. Neurological symptoms secondary to vertebral compression of cervical lesions have been reported in 3 of 26 patients with LCH and spinal lesions.[101] CNS LCH occurs most often in children with LCH of the pituitary or CNS-risk skull bones (mastoid, orbit, or temporal bone). Significant cognitive defects and MRI abnormalities may develop in some long-term survivors with CNS-risk skull lesions.[171] Some patients have markedly abnormal cerebellar function and behavior abnormalities, while others have subtle deficits in short-term memory and brain stem–evoked potentials.[83]
Skeletal. Orthopedic problems from lesions of the spine, femur, tibia, or humerus may be seen in 20% of patients. These problems include vertebral collapse or instability of the spine that may lead to scoliosis and facial or limb asymmetry.
Respiratory. Diffuse pulmonary disease may result in poor lung function with higher risk of infections and decreased exercise tolerance. These patients should be monitored with pulmonary function testing, including the diffusing capacity of carbon monoxide and ratio of residual volume to total lung capacity.[39]
Sources: 39
Digestive. Liver disease may lead to sclerosing cholangitis, which rarely responds to any treatment other than liver transplant.[129] Dental problems characterized by loss of teeth have been significant for some patients, usually related to overly aggressive dental surgery.[172]
Subsequent neoplasms. Bone marrow failure secondary to LCH or from therapy is rare and is associated with a higher risk of malignancy. Patients with LCH have a higher-than-normal risk of developing secondary cancers.[173,174] Leukemia (usually acute myeloid leukemia) occurs after treatment, as does lymphoblastic lymphoma. Concurrent LCH and malignancy has been reported in a few patients, and some patients had their malignancy first, followed by development of LCH. Three patients with T-cell acute lymphoblastic leukemia (ALL) and aggressive LCH were reported and, as with all histiocytic disorders associated with or following lymphoblastic malignancies, the same genetic changes were found in both diseases, suggesting a shared clonal origin.[175-177] One study reported two cases in which clonality with the same T-cell receptor gamma genotype was found.[176] The authors of this study emphasized the plasticity of lymphocytes developing into Langerhans cells. The second study described one patient with LCH after T-cell ALL who had the same T-cell receptor gene rearrangements and activating variants of the NOTCH1 gene.[177]
A publication based on surveying Histiocyte Society members and a literature review reported 116 cases of childhood LCH-malignancy pairs. Leukemias and myeloproliferative disorders (n = 58; 50.0%) prevailed over solid tumors (n = 43; 37.1%) and lymphomas (n = 15; 12.9%). In most children, malignancy followed LCH (n = 69; 59.5%). However, ALL, including T-cell ALL, was sometimes seen preceding the onset of LCH or histiocytic neoplasms. The histiocytic disorder commonly carried the same underlying genetic findings as the preceding leukemia.[178]
Sources: 178
Another study reported a population-based analysis of subsequent malignancies in pediatric patients in the Surveillance, Epidemiology, and End Results (SEER) Program database from 2000 to 2016.[179] Of the 936 pediatric cases, there were 2 cases of non-Hodgkin lymphoma, 2 cases of Hodgkin lymphoma, and 1 case of T-cell ALL. However, the median follow-up was 38 months, which may not be sufficient to capture secondary solid tumors.
Sources: 179
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The lack of clinical trials limits the ability to make evidence-based recommendations for adult patients with LCH.
Many investigators have previously recommended treatment according to the guidelines for childhood LCH. It is unclear, however, whether adult LCH responds as well as the childhood form of the disease. In addition, the drugs used in the treatment of children are not as well tolerated when used in adults. Excessive neurological toxicity from vinblastine, for example, prompted closure of the LCH-A1 trial. BRAF and MEK inhibitors are increasingly used as initial treatment for many adults.[1] For more information, see the Targeted therapies for the treatment of single-system and multisystem disease section.
Sources: 1 · Targeted therapies for the treatment of single-system and multisystem disease
An international expert consensus panel has proposed a treatment algorithm for adult patients and is summarized below.[1]
Sources: 1
Bone-only LCH: Treatment includes curettage, bisphosphonates, oral methotrexate, or hydroxyurea. Radiation therapy may be used for patients with progressive disease and fewer than three lesions. Patients with more than three lesions may receive chemotherapy (cladribine, cytarabine, or others) or MAPK inhibitors.
Skin-only LCH: Treatment includes hydroxyurea, oral methotrexate, thalidomide or lenalidomide, or topical therapy.
Single-system pulmonary LCH: Treatment is smoking cessation. Patients with progressive disease receive chemotherapy with similar drugs used for bone LCH.
Multisystem LCH: Treatment includes chemotherapy with similar drugs used for bone LCH.
Critical organ involvement (bone marrow, spleen, liver, brain): Patients with LCH and BRAF V600E variants receive a BRAF inhibitor. For patients without BRAF V600E variants, a MEK inhibitor may be used if tests are positive for MAPK variants. If no variants are found, patients receive chemotherapy based on the regimen used for bone LCH.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
It is difficult to judge the effectiveness of various treatments for pulmonary LCH because patients can recover spontaneously or have stable disease without treatment.
Treatment options for adult patients with pulmonary LCH include the following:
Smoking cessation. Smoking cessation is mandatory because of the apparent causal effect of smoking in pulmonary LCH.[45] Most adult patients with LCH have gradual disease progression with continued smoking. The disease may regress or progress with the cessation of smoking.[46] A study of 27 patients with pulmonary LCH observed that 52% of patients improved after a mean follow-up of 14 months. Most patients improved with smoking cessation, and some patients improved with steroid treatment. Four patients (15%) had stable disease at a mean follow-up of 26 months, and nine patients (33%) demonstrated disease progression during the mean follow-up of 22 months.[30][Level of evidence C3]
Sources: 45 · 46 · 30 · Level of evidence C3
Steroid therapy. It is not known whether steroid therapy is efficacious in the treatment of adult pulmonary LCH because reported case series did not control for smoking cessation.[45]
Sources: 45
Chemotherapy. Some patients have been reported to respond to treatment with cladribine or cytarabine.[45,47]; [15][Level of evidence C2]
Sources: 45 · 47 · 15 · Level of evidence C2
Lung transplant. Lung transplant may be necessary for adults with extensive pulmonary destruction from LCH.[22] One multicenter study reported a survival rate of 54% at 10 years posttransplant, with 20% of patients having recurrent LCH that did not impact survival. Longer follow-up of these patients is needed.[22] Another study confirmed a survival rate of approximately 50% at 10 years and improved hemodynamic changes associated with pulmonary arterial hypertension therapies, without oxygen worsening or pulmonary edema.[48]
The best strategy for follow-up of pulmonary LCH includes physical examination, chest radiographs, lung function tests, and high-resolution CT scans.[49]
Sources: 49
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for adult patients with bone LCH include the following:
Curettage followed by observation, with or without intralesional corticosteroids. As in children, adults with single-bone lesions should undergo curettage of the lesion followed by observation, with or without intralesional corticosteroids.[50] Extensive or radical surgery leading to loss of function and disfigurement is contraindicated at any site, including the teeth or jaw bones.
Sources: 50
Systemic chemotherapy. Systemic chemotherapy causes bone lesions to regress. A variety of chemotherapy regimens, including cytarabine and cladribine, have been used in the treatment of a relatively limited number of patients.[51,52] For more information, see the Chemotherapy and radiation therapy for the treatment of other single-system disease and multisystem disease section.
Sources: 51 · 52 · Chemotherapy and radiation therapy for the treatment of other single-system disease and multisystem disease
Low-dose radiation therapy. For patients who do not respond to chemotherapy, low-dose radiation therapy may be indicated and should be attempted before any radical surgery. Radiation therapy is also indicated for impending neurological deficits from vertebral body lesions or visual problems from orbital lesions. Two series and a study have reported the following:
Low-dose radiation therapy. For patients who do not respond to chemotherapy, low-dose radiation therapy may be indicated and should be attempted before any radical surgery. Radiation therapy is also indicated for impending neurological deficits from vertebral body lesions or visual problems from orbital lesions. Two series and a study have reported the following:
A German cooperative radiation therapy group reported on a series of 98 adult patients with LCH. Most of the patients (60 of 98) had only bone lesions and 24 had multisystem disease including bone, who were treated with radiation therapy.[53][Level of evidence C3] Of 89 evaluable patients, 77% achieved a complete remission, 9% developed an infield recurrence, and 15.7% (14 of 89) experienced a progression outside the radiation field(s).
Sources: 53 · Level of evidence C3
A retrospective analysis of 80 patients treated with radiation therapy alone reported a complete remission rate of 77% and a partial remission rate of 12.5%. The long-term control rate was 80% in adults. No adverse late effects were reported.[54][Level of evidence C3]
Sources: 54 · Level of evidence C3
A single-institution study included 39 patients with LCH (age range, 1.5–67 years; 24 patients aged >18 years) who received radiation therapy to 46 lesions. The study reported no local recurrences in the 31 bony sites. In comparison, the 3-year freedom from local failure rate was 63% in the 15 nonbone lesions (95% confidence interval, 32%–83%; P = .0008).[55]
Sources: 55
Bisphosphonate therapy. Case reports and case series have described the successful use of bisphosphonates, both intravenous pamidronate and oral zoledronate, in controlling severe bone pain in patients with multiple osteolytic LCH bone lesions.[56-58] A multi-institutional review of bisphosphonate therapy in children and adults with LCH found that most adult patients were given oral zoledronic acid, and most pediatric patients were given pamidronate.[59][Level of evidence C3] Because of the increased toxicity of chemotherapy in adults, bisphosphonate therapy could be used before chemotherapy in multifocal bone disease. Response of other organs, such as skin and soft tissue, to bisphosphonate therapy has been reported.[60]
Sources: 56 · 58 · 59 · Level of evidence C3 · 60
Anti-inflammatory agents with trofosfamide. Another approach using anti-inflammatory agents (pioglitazone and rofecoxib) coupled with trofosfamide in a specific timed sequence was successful in two patients who had disease resistant to standard chemotherapy treatment.[61][Level of evidence C3]
Sources: 61 · Level of evidence C3
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Treatment options for adult patients with single-system skin disease include the following:
Surgical excision. Localized lesions are rarely treated by surgical excision. Mutilating surgery, including hemivulvectomy, should be avoided unless the disease is refractory to all available therapy.
Topical therapy. Topical therapies are described in greater detail in the childhood isolated skin involvement section and include the following:
Sources: childhood isolated skin involvement
Topical therapy. Topical therapies are described in greater detail in the childhood isolated skin involvement section and include the following:
Topical or intralesional corticosteroid.
Topical tacrolimus.[62][Level of evidence C2]
Sources: 62 · Level of evidence C2
Topical imiquimod.[63,64][Level of evidence C3]
Sources: 63 · 64 · Level of evidence C3
Psoralen and long-wave ultraviolet A radiation (PUVA) and UVB. Therapies such as PUVA/UVB may be more useful in adults because long-term toxicity may be reduced.[62,65][Level of evidence C3]
Sources: 62 · 65 · Level of evidence C3
Systemic therapy. Systemic therapy for severe skin LCH includes oral methotrexate, hydroxyurea, oral thalidomide, oral interferon-alpha, or combinations of interferon and thalidomide.[66-68][Level of evidence C3] Interferon and thalidomide are also used to treat chronic skin LCH in adults.[69][Level of evidence C3] Recurrences are possible after treatment is stopped but lesions usually respond to re-treatment.Oral isotretinoin has induced remissions in some adult patients with refractory skin LCH.[70][Level of evidence C3]
Sources: 66 · 68 · Level of evidence C3 · 69 · Level of evidence C3 · 70 · Level of evidence C3
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Evidence (chemotherapy for the treatment of other single-system disease [not mentioned above] and multisystem disease):
A single-center, retrospective review of 58 adult patients with LCH reported on the efficacy and toxicities of treatment with vinblastine/prednisone, cladribine, and cytarabine.[51][Level of evidence C3]
Sources: 51 · Level of evidence C3
A single-center, retrospective review of 58 adult patients with LCH reported on the efficacy and toxicities of treatment with vinblastine/prednisone, cladribine, and cytarabine.[51][Level of evidence C3]
Patients treated with vinblastine/prednisone had the worst outcome, with 84% of patients not responding within 6 weeks or relapsing within a year.
The no-response/relapse rate was 59% for patients treated with cladribine and 21% for patients treated with cytarabine.
Grade 3 or 4 neurological toxic effects occurred in 75% of patients treated with vinblastine.
Grade 3 or 4 neutropenia occurred in 37% of patients treated with cladribine and in 20% of patients who received cytarabine.
One report evaluated adult patients who were treated with either vindesine and prednisone or cyclophosphamide, etoposide, vindesine, and prednisone.[71][Level of evidence C2]
Sources: 71 · Level of evidence C2
One report evaluated adult patients who were treated with either vindesine and prednisone or cyclophosphamide, etoposide, vindesine, and prednisone.[71][Level of evidence C2]
More than 70% of patients relapsed with either regimen.
Etoposide has been used with some success in adult patients with single-system and multisystem LCH.
Etoposide has been used with some success in adult patients with single-system and multisystem LCH.
Minimal toxicity was reported with the use of prolonged oral etoposide in adults with skin LCH, while 3-day courses of intravenous etoposide (100 mg/m2/day) induced complete remission in a small number of patients with resistant single-system and multisystem disease.[72][Level of evidence C3]
Sources: 72 · Level of evidence C3
Another study at the same center found that azathioprine was the most successful drug for localized disease in adults, with the addition of etoposide for refractory and multisystem disease.[73][Level of evidence C3]
Sources: 73 · Level of evidence C3
Cladribine is effective for adults with skin, bone, lymph node, and probably pulmonary and CNS disease.[74,75][Level of evidence C3]; [52]
Sources: 74 · 75 · Level of evidence C3 · 52
Cladribine is effective for adults with skin, bone, lymph node, and probably pulmonary and CNS disease.[74,75][Level of evidence C3]; [52]
In a retrospective multicenter study, 23 patients who had at least one previous therapy were treated with cladribine, using various dosing and treatment schedules.[76][Level of evidence C2] The overall response rate was 91%, and the complete response rate was 50%. A literature review identified an additional 48 patients who were treated with cladribine. The pooled analysis confirmed these results.
Sources: 76 · Level of evidence C2
A study reported on 38 patients with newly diagnosed or relapsed/refractory LCH treated with one to nine cycles of cladribine.[1][Level of evidence C2] The overall response rate was 79%. The complete response rate was 26%, and the partial response rate was 53%.[52]
Sources: 1 · Level of evidence C2 · 52
An adult lymphoma treatment regimen of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) was used in 11 patients.[77]
Sources: 77
An adult lymphoma treatment regimen of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) was used in 11 patients.[77]
The overall response rate was 100%, and the progression-free survival rate was 64%.
Methotrexate and cytarabine were given to 83 patients with newly diagnosed lung (68%), liver (28%), spleen (13%), or nonpituitary (4%) LCH.[78]
Sources: 78
Methotrexate and cytarabine were given to 83 patients with newly diagnosed lung (68%), liver (28%), spleen (13%), or nonpituitary (4%) LCH.[78]
The objective response rate was 88%, and one-third of the patients progressed after 3 years.
There was a high rate of grades 3 to 4 neutropenia, with nearly one-half of patients developing fevers.
One-third of patients had grades 3 to 4 thrombocytopenia.
In a study of 61 adult patients with LCH who were treated with subcutaneous cytarabine, the following results were reported:[79]
Sources: 79
In a study of 61 adult patients with LCH who were treated with subcutaneous cytarabine, the following results were reported:[79]
The estimated 3-year event-free survival (EFS) rate was 58.5%.
Poor prognostic factors for EFS included three or more involved organs and baseline lung involvement.
Grades 3 to 4 neutropenia occurred in 27.9% of patients.
Of the 61 patients, 47 completed 12 months of treatment, and 14 left the study (6 had a poor response to therapy and 8 decided to withdraw).
Radiation therapy. A report of stereotactic radiosurgery for the treatment of adult patients with pituitary LCH showed efficacy in reducing the masses.[80]
Sources: stereotactic radiosurgery · 80
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Early reports on the use of targeted therapies for adult patients with low-risk or high-risk LCH sites include the following:
MAP2K/ERK pathway inhibitors. The finding that most patients with LCH have BRAF or other RAS pathway variants led to several reports of good responses to vemurafenib, a BRAF V600E inhibitor, in adult patients with LCH and severe cutaneous LCH.[81-85][Level of evidence C3]Of four patients with LCH who were treated with vemurafenib on the VE-BASKET (NCT01524978) trial, one patient had a complete response and three patients had partial responses.[84][Level of evidence C3] One patient with LCH who was treated with vemurafenib had improvement in ataxia.[84][Level of evidence C3] One series reported on six patients who were treated with BRAF inhibitors as initial therapy.[86] Five patients had multisystem disease, and one patient had bone-only LCH. There were two complete responses, three partial responses, and one stable disease after 4 to 27 months of treatment.A proof-of-concept clinical trial of cobimetinib, an oral inhibitor of MEK1 and MEK2, was carried out in 18 adult patients with various histiocytoses, including histiocytic sarcomas. Patients were treated regardless of genomic findings. Responses were seen in patients with ARAF, BRAF, NRAS, KRAS, MAP2K1, and MAP2K2 variants. The overall response rate was 89%, with responses being durable. At 1 year, 94% of patients remained progression free.[83][Level of evidence C2]Early results of targeted inhibitor therapy are encouraging, but many questions remain, particularly the optimal duration of therapy and the reactivation rate after therapy is discontinued. A BRAF inhibitor in combination with a MEK inhibitor have been shown to be effective in patients with melanoma who have BRAF variants (with reduced toxicity). This combination may also be effective in patients with LCH, but it is generally not used for patients with histiocytic diseases.[81][Level of evidence C3] A number of clinical trials of BRAF and other RAS pathway inhibitors in adults and children with LCH are ongoing.
Sources: 81 · 85 · Level of evidence C3 · VE-BASKET (NCT01524978) · 84 · Level of evidence C3 · 84 · Level of evidence C3 · 86 · 83 · Level of evidence C2 · 81 · Level of evidence C3
Other targeted therapies. A case report suggests some benefit to treating neurodegenerative CNS LCH disease with infliximab, a tumor necrosis factor (TNF)-alpha inhibitor.[87][Level of evidence C3] However, the TNF inhibitors infliximab and etanercept have limited ability to cross the blood-brain barrier. Thalidomide, which also has anti-TNF activity, has been effective in adults with skin and bone LCH.[66,88][Level of evidence C3]; [88,89]
Sources: 87 · Level of evidence C3 · 66 · 88 · Level of evidence C3 · 88 · 89
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT04079179 (Cobimetinib for the Treatment of Refractory LCH): This study is open to children or adults with relapsed or refractory LCH or other newly diagnosed, relapsed, or refractory histiocytic disorders.
Sources: NCT04079179
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
LCH in organs such as the skin, bones, lymph nodes, or pituitary gland usually gets better with treatment and is called "low-risk." LCH in the spleen, liver, or bone marrow is harder to treat and is called "high-risk." Children with LCH in high-risk organs and the gastrointestinal tract have a greater risk of not responding to treatment than patients with high-risk LCH and no disease in the gastrointestinal tract. High-risk LCH is usually seen in children younger than 2 years.
Sources: pituitary gland · spleen · gastrointestinal tract · responding
The prognosis and treatment options depend on the following:
Sources: prognosis
Which organs or body systems are affected by LCH.
How many organs or body systems the LCH affects.
Whether LCH is found in the liver, spleen, bone marrow, or certain bones in the skull.
How quickly LCH responds to initial treatment.
Whether there are certain mutations in the BRAF gene.
Whether LCH has just been diagnosed or has come back (recurred).
Sources: recurred
In infants up to 1 year of age, LCH may go away without treatment.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
LCH is described as single-system disease or multisystem disease, depending on how many body systems are affected:
Single-system LCH: LCH is found in one part of an organ or body system or in more than one part of that organ or body system. Bone is the most common single place for LCH to be found.
Sources: organ
Multisystem LCH: LCH is found in two or more organs or body systems or may be found throughout the body. Multisystem LCH is less common than single-system LCH.
LCH may affect low-risk organs or high-risk organs:
Low-risk organs include the skin, bone, lungs, lymph nodes, gastrointestinal tract, pituitary gland, thyroid gland, thymus, and central nervous system (CNS).
Sources: lungs · lymph nodes · gastrointestinal tract · pituitary gland · thyroid gland · thymus · central nervous system
High-risk organs include the liver, spleen, and bone marrow.
Sources: liver · spleen · bone marrow
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Progressive LCH describes LCH that continues to grow, spread, or get worse. Progressive disease may be a sign that the LCH has become refractory to treatment.
Sources: Progressive · refractory
Refractory LCH describes LCH that does not respond to initial treatment.
Sources: respond
Recurrent or reactivated LCH describes LCH that has come back after it has been treated.
Sources: Recurrent · reactivated
Many patients with LCH get better with treatment. However, when treatment stops, new lesions may appear or old lesions may come back. This is called reactivation (recurrence) and may occur within 1 year after stopping treatment. Patients with multisystem disease are more likely to have a reactivation. Common sites of reactivation are bone, ears, or skin. Diabetes insipidus also may develop. Less common sites of reactivation include lymph nodes, bone marrow, spleen, liver, or lung. Some patients may have more than one reactivation.
Sources: lesions · Diabetes insipidus
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
There are different types of treatment for patients with Langerhans cell histiocytosis (LCH).
Children with LCH should have their treatment planned by a team of health care providers who are experts in treating childhood cancer or LCH.
Nine types of standard treatment are used to treat LCH.
Nine types of standard treatment are used to treat LCH.
Chemotherapy
Surgery
Radiation therapy
Photodynamic therapy
Immunotherapy
Targeted therapy
Other drug therapy
Stem cell transplant
Observation
New types of treatment are being tested in clinical trials.
Treatment for Langerhans cell histiocytosis may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their treatment.
Follow-up tests may be needed.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Different types of treatments are available for patients with LCH. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Whenever possible, patients should take part in a clinical trial in order to receive new types of treatment for LCH. Some clinical trials are open only to patients who have not started treatment.
Sources: LCH · standard · clinical trials · research study · cancer
Clinical trials are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI website. Choosing the most appropriate treatment is a decision that ideally involves the patient, family, and health care team.
Sources: NCI website
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with LCH and who specialize in certain areas of medicine. These may include the following specialists:
Sources: pediatric oncologist · pediatric · health care providers · medicine · specialists
Pediatrician.
Sources: Pediatrician
Pediatric surgeon.
Sources: Pediatric surgeon
Pediatric hematologist.
Sources: Pediatric hematologist
Radiation oncologist.
Sources: Radiation oncologist
Neurologist.
Sources: Neurologist
Endocrinologist.
Sources: Endocrinologist
Pediatric nurse specialist.
Sources: Pediatric nurse specialist
Rehabilitation specialist.
Sources: Rehabilitation specialist
Psychologist.
Sources: Psychologist
Social worker.
Sources: Social worker
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Although it is unknown whether LCH is a type of cancer, some of the treatments used for cancer are effective at treating LCH.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy that is taken by mouth or injected into a vein or muscle enters the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Chemotherapy may also be applied to the skin in a cream or lotion (topical chemotherapy).
Sources: Chemotherapy · drugs · cells · injected · vein · systemic chemotherapy · topical chemotherapy
Chemotherapy may be given by injection, by mouth, or applied to the skin to treat LCH.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Surgery may be used to remove LCH lesions and a small amount of nearby healthy tissue. Curettage is a type of surgery that uses a curette (a sharp, spoon-shaped tool) to scrape LCH cells from bone.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Ultraviolet B (UVB) radiation therapy may be given using a special lamp that directs radiation toward LCH skin lesions.
Sources: Radiation therapy · x-rays · radiation · External radiation therapy · Ultraviolet B
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Photodynamic therapy is a cancer treatment that uses a drug and a certain type of laser light to kill cancer cells. A drug that is not active until it is exposed to light is injected into a vein. The drug collects more in cancer cells than in normal cells. For LCH, laser light is aimed at the skin and the drug becomes active and kills the cancer cells. Photodynamic therapy causes little damage to healthy tissue. Patients who have photodynamic therapy should not spend too much time in the sun.
Sources: Photodynamic therapy · laser
In one type of photodynamic therapy, called psoralen and ultraviolet A (PUVA) therapy, the patient receives a drug called psoralen and then ultraviolet A radiation is directed to the skin.
Sources: psoralen and ultraviolet A · psoralen · ultraviolet A radiation
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. Thalidomide is a type of immunotherapy used to treat LCH.
Sources: Immunotherapy · immune system · Thalidomide
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. There are different types of targeted therapy:
Sources: Targeted therapy
BRAF inhibitors block proteins needed for cell growth and may kill cancer cells. The BRAF gene is found in a mutated (changed) form in some LCH and blocking it may help keep LCH cells from growing.
Sources: BRAF inhibitors · proteins · gene · mutated
BRAF inhibitors block proteins needed for cell growth and may kill cancer cells. The BRAF gene is found in a mutated (changed) form in some LCH and blocking it may help keep LCH cells from growing.
Vemurafenib and dabrafenib are BRAF inhibitors used to treat LCH.
Sources: Vemurafenib · dabrafenib
MEK inhibitors block proteins called MEK1 and MEK2 that affect the growth and survival of cancer cells.
Sources: MEK inhibitors · MEK1 · MEK2
MEK inhibitors block proteins called MEK1 and MEK2 that affect the growth and survival of cancer cells.
Trametinib is a MEK inhibitor that is being studied in the treatment of certain childhood tumors for use alone or combined with dabrafenib.
Sources: Trametinib · dabrafenib
Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.
Sources: Monoclonal antibodies · immune system · proteins · infusion · toxins · radioactive
Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.
Rituximab is a monoclonal antibody used to treat LCH.
Sources: Rituximab
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Other drugs used to treat LCH include the following:
Steroid therapy, such as prednisone, is used to treat LCH lesions.
Sources: Steroid therapy · prednisone
Bisphosphonate therapy (such as pamidronate, zoledronate, or alendronate) is used to treat LCH lesions of the bone and to lessen bone pain.
Sources: Bisphosphonate · therapy · pamidronate · zoledronate · alendronate
Anti-inflammatory drugs are drugs (such as pioglitazone and rofecoxib) that are commonly used to decrease fever, swelling, pain, and redness. Anti-inflammatory drugs and chemotherapy may be given together to treat adults with bone LCH.
Sources: Anti-inflammatory drugs · pioglitazone · rofecoxib · fever
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Chemotherapy is given to kill cancer cells. Healthy cells, including blood-forming cells, are destroyed by the LCH treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These stem cells grow into (and restore) the body's blood cells.
Sources: Stem cell transplant · bone marrow · donor · infusion
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Observation is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change.
Sources: Observation · monitoring · condition · signs · symptoms
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:
Sources: late effects
Slow growth and development.
Hormone imbalance.
Sources: Hormone
Hearing loss.
Bone, tooth, liver, and lung problems.
Changes in mood, feeling, behavior, learning, thinking, or memory.
Second cancers, such as leukemia, lymphoma, retinoblastoma, Ewing sarcoma, brain or liver cancer.
Sources: Second cancers · leukemia · lymphoma · retinoblastoma · Ewing sarcoma · brain · liver cancer
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. For more information, see Late Effects of Treatment for Childhood Cancer.
Many patients with multisystem LCH have late effects caused by treatment or by the disease itself. These patients often have long-term health problems that affect their quality of life.
Sources: quality of life
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
LCH patients should be monitored for many years because of the risk of reactivation (recurrence). Some of the tests that were done to diagnose LCH may be repeated. This is to see how well the treatment is working and if there are any new lesions. These tests may include:
Sources: recurrence · diagnose
Physical exam.
Sources: Physical exam
Neurological exam.
Sources: Neurological exam
Ultrasound exam.
Sources: Ultrasound exam
MRI.
Sources: MRI
CT scan.
Sources: CT scan
PET scan.
Sources: PET scan
Other tests that may be needed include:
Brain stem auditory evoked response (BAER) test: A test that measures the brain's response to clicking sounds or certain tones to detect some types of hearing loss.
Pulmonary function test (PFT): A test to see how well the lungs are working. It measures how much air the lungs can hold and how quickly air moves into and out of the lungs. It also measures how much oxygen is used and how much carbon dioxide is given off during breathing. This is also called a lung function test.
Sources: Pulmonary function test · oxygen · carbon dioxide
Chest x-ray: An x-ray of the organs and bones inside the chest. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.
Sources: Chest x-ray
The results of these tests can show if your condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Sources: follow-up
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment of newly diagnosed childhood Langerhans cell histiocytosis (LCH) skin lesions may include:
Sources: Langerhans cell histiocytosis · lesions
Observation. Young children with skin-only LCH lesions should be followed over a period of many years due to a risk of diabetes insipidus.
Sources: Observation · diabetes insipidus
When severe rashes, pain, ulceration, or bleeding occur, treatment may include the following:
Sources: rashes · ulceration
Steroid therapy.
Sources: Steroid therapy
Chemotherapy given by mouth or vein.
Sources: Chemotherapy · vein
Chemotherapy applied to the skin.
Photodynamic therapy with psoralen and ultraviolet A (PUVA) therapy.
Sources: Photodynamic therapy · psoralen and ultraviolet A
UVB radiation therapy.
Sources: UVB radiation · therapy
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment of newly diagnosed childhood LCH bone lesions in the front, sides, or back of the skull, or in any other single bone may include:
Surgery (curettage) with or without steroid therapy.
Sources: Surgery · curettage · steroid therapy
Low-dose radiation therapy for lesions that affect nearby organs, or are painful and cannot be treated with other therapy.
Sources: Low-dose radiation therapy · organs
Treatment of newly diagnosed childhood LCH lesions in bones around the ears or eyes is done to lower the risk of diabetes insipidus and other long-term problems. Treatment may include:
Sources: diabetes insipidus
Chemotherapy and steroid therapy.
Sources: Chemotherapy
Surgery (curettage).
Treatment of newly diagnosed childhood LCH lesions of the spine or thigh bone may include:
Sources: spine
Observation.
Sources: Observation
Low-dose radiation therapy.
Chemotherapy, for lesions that spread from the spine into nearby tissue.
Sources: tissue
Surgery to strengthen the weakened bone by bracing or fusing the bones together.
Treatment of two or more bone lesions may include:
Chemotherapy and steroid therapy.
Treatment of two or more bone lesions combined with skin lesions, lymph node lesions, or diabetes insipidus may include:
Sources: lymph node
Chemotherapy with or without steroid therapy.
Bisphosphonate therapy.
Sources: Bisphosphonate · therapy
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment of newly diagnosed childhood LCH central nervous system (CNS) lesions may include:
Sources: LCH · central nervous system · lesions
Chemotherapy with or without steroid therapy.
Sources: Chemotherapy · steroid therapy
Treatment of newly diagnosed LCH CNS neurodegenerative syndrome may include:
Sources: neurodegenerative syndrome
Targeted therapy with BRAF inhibitors (vemurafenib or dabrafenib).
Sources: Targeted therapy · BRAF inhibitors · vemurafenib · dabrafenib
Chemotherapy.
Targeted therapy with a monoclonal antibody (rituximab).
Sources: monoclonal antibody · rituximab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed childhood LCH multisystem disease lesions in the spleen, liver, or bone marrow and another organ or site may include:
Sources: diagnosed · LCH · lesions · spleen · liver · bone marrow · organ
Chemotherapy and steroid therapy. Higher doses of more than one chemotherapy drug and steroid therapy may be given to patients whose tumors do not respond to initial chemotherapy.
Sources: Chemotherapy · steroid therapy · doses · tumors · respond
Targeted therapy (vemurafenib).
Sources: Targeted therapy · vemurafenib
A liver transplant for patients with severe liver damage.
Sources: transplant
A clinical trial that tailors the patient's treatment based on features of the LCH at diagnosis and how it responds to treatment.
A clinical trial of chemotherapy and steroid therapy.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of progressive, refractory, or recurrent low-risk LCH may include:
Sources: progressive · refractory · recurrent
Chemotherapy with or without steroid therapy.
Sources: Chemotherapy · steroid therapy
Bisphosphonate therapy.
Sources: Bisphosphonate · therapy
Treatment of progressive, refractory, or recurrent high-risk multisystem LCH may include:
Chemotherapy.
Targeted therapy (vemurafenib).
Sources: Targeted therapy · vemurafenib
Stem cell transplant.
Sources: Stem cell transplant
Treatments being studied for progressive, refractory, or recurrent childhood LCH include the following:
A clinical trial that tailors the patient's treatment based on features of the LCH at diagnosis and how it responds to treatment.
Sources: clinical trial · diagnosis · responds
A clinical trial of targeted therapy (trametinib and dabrafenib).
Sources: trametinib · dabrafenib
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Langerhans cell histiocytosis (LCH) in adults is a lot like LCH in children and can form in the same organs and systems as it does in children. These include the endocrine and central nervous systems, liver, spleen, bone marrow, and gastrointestinal tract. In adults, LCH is most commonly found in the lung as a single-system disease. In some patients, other organs may be involved, including bone, skin, hypothalamus, or pituitary gland. LCH in the lung occurs more often in young adults who smoke.
Sources: Langerhans cell histiocytosis · organs · endocrine · central nervous systems · liver · spleen · bone marrow · gastrointestinal tract · lung · hypothalamus · pituitary gland
As in children, the signs and symptoms of LCH depend on where it is found in the body. See the General Information section for the signs and symptoms of LCH.
Sources: symptoms · General Information
Tests that examine the organs and body systems where LCH may occur are used to detect (find) and diagnose LCH. See the General Information section for tests and procedures used to diagnose LCH.
Sources: diagnose · General Information
In adults, there is not a lot of information about what treatment works best. Sometimes, information comes only from reports of the diagnosis, treatment, and follow-up of one adult or a small group of adults who were given the same type of treatment.
Sources: follow-up
Adult patients with LCH have higher rates of other cancers than do adults of the same age without LCH. These cancers may be found before, at the same time, or after an LCH diagnosis, and occur more in patients who smoke.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Quitting smoking. Lung damage will get worse over time in patients who do not quit smoking. In patients who quit smoking, lung damage may get better or it may get worse over time.
Chemotherapy.
Sources: Chemotherapy
Lung transplant for patients with severe lung damage.
Sources: transplant
Steroid therapy.
Sources: Steroid therapy
Sometimes LCH of the lung will go away or not get worse even if it's not treated.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment for LCH that affects only the bone in adults may include:
Sources: LCH
Surgery with or without steroid therapy.
Sources: Surgery · steroid therapy
Chemotherapy.
Sources: Chemotherapy
Radiation therapy.
Sources: Radiation therapy
Bisphosphonate therapy, for severe bone pain.
Sources: Bisphosphonate · therapy
Anti-inflammatory drugs (pioglitazone or rofecoxib) with chemotherapy.
Sources: Anti-inflammatory drugs · pioglitazone · rofecoxib
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment for LCH that affects only the skin in adults may include:
Sources: LCH
Surgery.
Sources: Surgery
Steroid or other drug therapy (tacrolimus or imiquimod) applied or injected into the skin.
Sources: Steroid · drug therapy · tacrolimus · imiquimod · injected
Photodynamic therapy with psoralen and ultraviolet A (PUVA) radiation.
Sources: Photodynamic therapy · psoralen and ultraviolet A
UVB radiation therapy.
Sources: UVB radiation · therapy
Chemotherapy or immunotherapy given by mouth, such as methotrexate, thalidomide, or hydroxyurea.
Sources: Chemotherapy · immunotherapy · methotrexate · thalidomide · hydroxyurea
Treatment for LCH that affects the skin and other body systems in adults may include:
Chemotherapy.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Treatment of single-system and multisystem disease in adults that does not affect the lung, bone, or skin may include:
Sources: lung
Chemotherapy.
Sources: Chemotherapy
Radiation therapy.
Sources: Radiation therapy
Targeted therapy (vemurafenib).
Sources: Targeted therapy · vemurafenib
For more about LCH trials for adults, see the Histiocyte Society website.
Sources: LCH · Histiocyte Society
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Childhood Langerhans Cell Histiocytosis
ClinicalTrials.gov recordMultiple Myeloma, Neoplasms
ClinicalTrials.gov recordLangerhans Cell Histiocytosis
ClinicalTrials.gov recordLangerhans Cell Histiocytosis
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent...
ClinicalTrials.gov recordLangerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma,...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma,...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell...
ClinicalTrials.gov recordLangerhans Cell Histiocytosis
Treatment of recurrent, refractory, or progressive low-risk disease: single-system or multisystem LCH